Cencora Boosts Guidance After Strong Q3 2026 Results
Event summary
- Cencora reported Q3 2026 revenue of $84.8B, up 5.1% YoY.
- Adjusted diluted EPS increased 12.0% to $4.48 from $4.00.
- Raised fiscal 2026 adjusted diluted EPS guidance to $17.75-$17.95.
- Acquisition of OneOncology in February 2026 drove gross profit growth.
- Good Neighbor Pharmacy ranked #1 in J.D. Power 2026 U.S. Pharmacy Study.
The big picture
Cencora's strong Q3 results reflect its strategic focus on pharmaceutical-centric solutions and successful integration of recent acquisitions. The company's investments in specialty, digital transformation, and talent are positioning it for sustainable long-term growth amidst a competitive healthcare ecosystem. With raised guidance and continued market leadership, Cencora is reinforcing its value proposition to stakeholders.
What we're watching
- Integration Success
- How OneOncology acquisition will impact long-term growth.
- Market Positioning
- Whether Cencora can sustain its leadership in specialty pharmacy services.
- Regulatory Compliance
- The pace at which opioid-related litigation impacts financials.
Related topics